EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer

Patrick M Boland iD, Heinz-Josef Lenz iD, Kristen K Ciombor iD, Vaia Florou iD, Michael J Pishvaian iD, Michael Cusnir iD, Deirdre Cohen iD, Jessie Y Guo iD, Min Tang, Prabhu Rajagopalan iD, Sandra E Wiley iD, Richard G Ghalie iD und 1 weitere

Investigational New Drugs · 27.12.2024

DOI: 10.1007/s10637-024-01489-1 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Investigational New Drugs, online erschienen am 27.12.2024. Verfasst von Patrick M Boland und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Pb564@cinj.rutgers.edu. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respiration as the primary source of energy. In turn, the addition of an inhibitor of mitochondrial respiration to antiangiogenic therapy holds potential to induce synthetic lethality. This study evaluated the mitochondrial inhibitor ME-344 in combination with bevacizumab in patients with refractory metastatic colorectal cancer (mCRC). Patients were eligible if they had disease progression after standard therapies, adequate hematologic, hepatic and renal function, and no contraindications to bevacizumab. ME-344 was administered intravenously on days 1, 8 and 15 and bevacizumab on days 1 and 15 of 28-day cycles until disease progression or intolerance. The primary efficacy endpoint was progression-free survival (PFS) at week 16. In the 23 patients enrolled, the median age was 58 years, median number of prior lines of therapy was 4, and median interval from last therapy was 3 months. The most common adverse events (all grades/grade ≥ 3) were fatigue (48%/13%), abdominal pain (35%/4%), diarrhea (30%/4%) and constipation (30%/0%). No patient had an objective response; 9 patients (39%) achieved stable disease. The 16-week PFS was 30.6% (95% confidence interval [CI]: 12.2–51.3), the median PFS was 1.9 months (95% CI: 1.6–4.7), and the median overall survival was 6.7 months (95% CI: 3.4-not reached). ME-344 plus bevacizumab was well tolerated. Disease control was limited in this heavily pretreated patient population. Additional investigations in earlier lines are indicated, and extended-release ME-344 formulations may provide longer drug exposure to maximize benefit. (Trial registration number ClinicalTrials.gov NCT05824559. Registration date 22 March 2022).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabColorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedMaleFemaleAgedAdultProgression-Free SurvivalOxidative PhosphorylationAngiogenesis InhibitorsNeoplasm Metastasis

Stichwörter der Autor:innen

Colorectal cancerME-344Metabolic synthetic lethalityMetabolomicsOxPhos inhibitionVEGF

Substanzen

BevacizumabAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Division of Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Pb564@cinj.rutgers.edu.
  • Rutgers Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ, 08901, USA. Pb564@cinj.rutgers.edu.
  • Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Division of Oncology, Huntsman Cancer Institute of the University of Utah, Salt Lake City, UT, USA.
  • Department of Medicine, Johns Hopkins Kimmel Cancer Center, Washington, DC, USA.

ORCID-Profile: Patrick M Boland, Heinz-Josef Lenz, Kristen K Ciombor, Vaia Florou, Michael J Pishvaian, Michael Cusnir, Deirdre Cohen, Jessie Y Guo, Prabhu Rajagopalan, Sandra E Wiley, Richard G Ghalie, Howard S Hochster

Zitieren

APA

Boland, P. M., Lenz, H. J., Ciombor, K. K., Florou, V., Pishvaian, M. J., Cusnir, M., Cohen, D., Guo, J. Y., Tang, M., Rajagopalan, P., Wiley, S. E., Ghalie, R. G., & Hochster, H. S. (2024). A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01489-1

Vancouver

Boland PM, Lenz HJ, Ciombor KK, Florou V, Pishvaian MJ, Cusnir M, et al. A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01489-1

BibTeX
@article{Boland2024,
  author = {Boland, Patrick M and Lenz, Heinz-Josef and Ciombor, Kristen K and Florou, Vaia and Pishvaian, Michael J and Cusnir, Michael and Cohen, Deirdre and Guo, Jessie Y and Tang, Min and Rajagopalan, Prabhu and Wiley, Sandra E and Ghalie, Richard G and Hochster, Howard S},
  title = {A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01489-1}
}
Kostenlos starten →